Investment Thesis — MetLife, Inc.
MetLife is priced as if its core insurance business faces secular decline, yet the market overlooks its ability to reprice risk and expand margins in a higher-rate environment. The recent sell-off reflects backward-looking fears, not the forward earnings power embedded in its asset base.
Catalysts
- Sustained higher interest rates
- Accelerated capital return (buybacks/dividends)
- Improved underwriting results
Risk Factors
- Sharp decline in interest rates
- Unexpected surge in claims or credit losses
- Regulatory changes impacting capital requirements
Key Debates
Fwd P/E expands to 9.0x by Q4 2024
MET reaches $95 analyst target by H1 2025
2.90% Fwd Revenue Growth accelerates to 4% by Q3